Bacitracin: complete guide

Bacitracin is a cyclic polypeptide antibiotic sold in first aid products. This guide covers its structure, mechanism, labeled uses, evidence, FDA status and lab use.

Complete guide6 min read

Key takeaway

Bacitracin is a complex of cyclic polypeptides, mainly bacitracin A, made by Bacillus bacteria. Bacitracin A weighs 1,422.7 g/mol. Over-the-counter first aid products remain on the market. On January 31, 2020, FDA asked all holders of bacitracin for injection to seek withdrawal, citing kidney toxicity and severe allergic reactions.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of ANDA 061212 on November 9, 1971.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited2 in this article · 2 across 1 article on Bacitracin
Related productsBPC-157, TB-500 and thymic peptides

Bacitracin is a ring-shaped polypeptide antibiotic found in first aid ointments. Its regulatory story changed in 2020, when FDA asked makers to withdraw one form of the drug. This guide covers its structure, mechanism, labeled uses, evidence, safety and lab use. Sources were checked on November 17, 2026.

Quick answer: Bacitracin is a polypeptide antibiotic that blocks bacterial cell-wall building. Current labels cover first aid use on minor cuts, scrapes and burns, and some eye infections. FDA has withdrawn approval of the injectable form. Labs also use bacitracin susceptibility to help identify group A streptococci.

Vitrapep does not sell bacitracin; this page is a reference summary of published research and regulatory information.

What is bacitracin?

Bacitracin is not one molecule. The NCI Thesaurus, quoted in PubChem, calls it “a complex of cyclic polypeptide antibiotics, mainly bacitracin A.” MeSH describes the commercial preparation as “a mixture of at least nine bacitracins with bacitracin A as the major constituent.” MeSH says it is produced by the Tracy-I strain of Bacillus subtilis (PubChem CID 10909430).

It is a peptide because its backbone is a chain of amino acids. ChEBI describes bacitracin A as “a polypeptide and a homodetic cyclic peptide.” Part of the chain closes into a ring, and one unit contains a sulfur-bearing thiazoline ring. PubChem lists bacitracin A as C66H103N17O16S, with a molecular weight of 1,422.7 g/mol. See our guide to types of peptides for how cyclic peptides fit in.

The earliest bacitracin approval we could verify in Drugs@FDA is ANDA 061212, a bacitracin eye ointment. Drugs@FDA lists the original approval of ANDA 061212 on November 9, 1971. That product is now listed as discontinued (Drugs@FDA).

Table 1

Bacitracin: key facts

Fact Detail
Structure type Complex of cyclic polypeptides, mainly bacitracin A
Class Cyclic polypeptide antibacterial
Molecular formula C66H103N17O16S (bacitracin A)
Molecular weight 1,422.7 g/mol (bacitracin A)
First FDA approval Earliest verified: November 9, 1971 (ANDA 061212, now discontinued)
Brand names (US) Generic bacitracin and bacitracin zinc labels; combination products with polymyxin B

How does bacitracin work?

Bacteria build their cell wall from peptidoglycan. A lipid carrier moves the building blocks across the cell membrane. The NCI Thesaurus states that “Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule.” The result, per the same source, is that bacitracin “prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth.”

FDA’s pharmacologic class text, also in PubChem, describes the effect as “Decreased Cell Wall Synthesis & Repair.” A bacitracin eye ointment label says it acts against “many gram-positive pathogens” and is “ineffective against fungi” (bacitracin eye ointment label). Like vancomycin, it targets cell-wall building, but at a different step.

What is bacitracin approved for?

First aid. Many bacitracin zinc products are sold over the counter under FDA’s OTC monograph M004. A Sun Pharmaceutical label is an example. Its stated purpose is “First aid antibiotic.” Its uses read: “first aid to help prevent infection in” minor cuts, scrapes and burns (Sun Pharmaceutical label, 2026).

Eye infections. The ANDA 061212 eye ointment label lists “the treatment of superficial ocular infections involving the conjunctiva and/or cornea” caused by susceptible organisms. Drugs@FDA now lists that product as discontinued.

Injectable form withdrawn. FDA no longer approves bacitracin for injection. A 2022 Federal Register notice explains why. “On January 31, 2020, FDA requested that all application holders of bacitracin for injection” voluntarily seek withdrawal. The notice states that bacitracin for injection “poses serious risks, including nephrotoxicity and anaphylactic reactions.” FDA’s Antimicrobial Drugs Advisory Committee met in April 2019 and voted that its risks outweigh its benefits. Xellia’s approval was withdrawn as of July 11, 2022 (87 FR 41135).

What does the key evidence show?

Bacitracin predates modern trial standards. One randomized human trial tested it in wound care after skin surgery. This randomized, double-blind trial enrolled 922 patients with 1,249 surgical wounds. It compared bacitracin ointment with plain white petrolatum.

Infection rates were low in both groups: 2.0% (9 of 440) with petrolatum and 0.9% (4 of 444) with bacitracin. The difference was not significant (P = .37). No petrolatum patient developed allergic contact dermatitis, compared with 4 bacitracin patients (0.9%; P = .12) (Smack et al., 1996). In short, the trial found no significant infection benefit over petrolatum in clean surgical wounds, with a small number of allergic reactions.

The 2019 advisory committee vote is the other key piece of evidence. It weighed the injectable form’s risks against its benefits and found the risks greater.

What side effects does the label list?

Bacitracin labels are older and shorter than modern prescribing information, and none we read has a boxed warning. The ANDA 061212 eye ointment label says bacitracin has “such a low incidence of allergenicity” that side reactions are practically nonexistent. It lists hypersensitivity to bacitracin as a contraindication. The Sun Pharmaceutical OTC label’s warnings name rash and other allergic reactions.

The withdrawn injectable form was different. FDA cited nephrotoxicity (kidney toxicity) and anaphylactic reactions when it asked for withdrawal.

On resistance, the WHO 2024 List of Medically Important Antimicrobials places cyclic polypeptides, including bacitracin, in its “important antimicrobials” tier. That is the lowest of its four tiers for medically important drugs (WHO, 2024).

What is bacitracin’s regulatory status, and how is it used in research?

Bacitracin first aid products are sold over the counter under OTC monograph M004. DailyMed lists hundreds of bacitracin-containing labels, many updated in 2026. Some eye products combine bacitracin zinc with polymyxin B; our polymyxin B and colistin guide covers that partner drug. The injectable form is no longer approved.

In the microbiology lab, bacitracin helps sort streptococci. In a study published in CDC’s Emerging Infectious Diseases, researchers wrote: “We tested β-hemolytic isolates for susceptibility to bacitracin.” They then used a grouping kit to confirm the Lancefield group of each isolate (Yang et al., 2013). This is an in vitro lab use, not a treatment.

Frequently asked questions about bacitracin

Is bacitracin a peptide?

Yes. It is a mixture of cyclic polypeptides. Its main component, bacitracin A, is a ring-closed chain of amino acids.

Why did FDA pull bacitracin for injection?

FDA cited serious risks, including nephrotoxicity and anaphylactic reactions. Its advisory committee voted in April 2019 that the risks outweighed the benefits.

Is bacitracin ointment still sold?

Yes. Bacitracin zinc first aid products remain on the market under OTC monograph M004, and DailyMed lists many current labels.

How does bacitracin kill bacteria?

It binds C55-isoprenyl pyrophosphate, a lipid carrier needed to build the cell wall. Without that carrier, peptidoglycan synthesis stops.

Did bacitracin beat petrolatum in wound care?

Not significantly. In a 922-patient trial, infection rates were 0.9% with bacitracin and 2.0% with petrolatum (P = .37).

What to know now

  • Structure: complex of cyclic polypeptides, mainly bacitracin A (1,422.7 g/mol).
  • Mechanism: binds the lipid carrier C55-isoprenyl pyrophosphate and blocks cell-wall synthesis.
  • Current use: OTC first aid products under monograph M004.
  • Withdrawn: FDA asked for withdrawal of the injectable form on January 31, 2020, citing kidney toxicity and anaphylaxis.
  • Evidence: no significant infection benefit over petrolatum in a 922-patient surgical wound trial.
  • Lab use: bacitracin susceptibility helps identify group A streptococci.

What we’re watching

Changes to FDA’s OTC monograph M004, which governs first aid antibiotic products. Future revisions of the WHO List of Medically Important Antimicrobials. Related guides: polymyxin B and colistin and vancomycin.

More for immune system

All 24 compounds for immune system

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 10909430, bacitracin; U.S. Food and Drug Administration. Drugs@FDA: ANDA 061212 (bacitracin) . Retrieved November 17, Drugs@FDA: ANDA 061212 (bacitracin); Rebel Distributors Corp 2011, Bacitracin ophthalmic ointment USP; Sun Pharmaceutical Industries 2026, Bacitracin zinc ointment Drug Facts; U.S. Food and Drug Administration 2022, Federal Register, 87; Smack 1996, JAMA, 276; World Health Organization 2024; Yang 2013, Streptococcus; U.S. National Library of Medicine 2026, DailyMed SPL listing: bacitracin. All 9 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 10909430, bacitracin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/10909430
  2. U.S. Food and Drug Administration. Drugs@FDA: ANDA 061212 (bacitracin). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061212
  3. Rebel Distributors Corp. (2011). Bacitracin ophthalmic ointment USP (ANDA 061212; manufactured for Fera Pharmaceuticals). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3dc310a-3d75-4e1e-9f9f-ed5c77ff7bfe
  4. Sun Pharmaceutical Industries, Inc. (2026). Bacitracin zinc ointment Drug Facts (OTC monograph M004). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4afdeedf-9cdf-47d6-919f-ea907fda0290
  5. U.S. Food and Drug Administration. (2022, July 11). Xellia Pharmaceuticals USA, LLC; withdrawal of approval of an abbreviated new drug application for bacitracin for injection. Federal Register, 87(131), 41135–41136. https://www.govinfo.gov/content/pkg/FR-2022-07-11/html/2022-14680.htm
  6. Smack, D. P., et al. (1996). Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment: A randomized controlled trial. JAMA, 276(12), 972–977. https://pubmed.ncbi.nlm.nih.gov/8805732/
  7. World Health Organization. (2024). WHO List of Medically Important Antimicrobials: A risk management tool for mitigating antimicrobial resistance due to non-human use. https://cdn.who.int/media/docs/default-source/gcp/who-mia-list-2024-lv.pdf
  8. Yang, P., et al. (2013). Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011. Emerging Infectious Diseases, 19(6), 909–915. https://doi.org/10.3201/eid1906.121020
  9. U.S. National Library of Medicine. (2026). DailyMed SPL listing: bacitracin (669 labels). Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=bacitracin